Neo-Tomizol (Carbimazole)

Carbimazole is converted in the body to methimazole, which blocks the enzyme thyroid peroxidase. This inhibition prevents iodination of tyrosine residues in thyroglobulin and the coupling steps needed to form thyroid hormones, thereby reducing the synthesis of T3 and T4.

The exact dose of Neo‑Tomizol is determined by the prescribing clinician based on the severity of the thyroid disorder, patient age, weight, and response to therapy. Physicians typically start with a low dose and adjust gradually, monitoring thyroid function tests and clinical response.

Carbimazole crosses the placenta and is excreted in breast milk. Use during pregnancy or lactation is only recommended when the potential benefit outweighs the risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative management strategies when appropriate.

To order Neo‑Tomizol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

The primary alternative to carbimazole is propylthiouracil (PTU). Both inhibit thyroid hormone synthesis, but carbimazole is generally preferred for long‑term management because it has a more favorable safety profile and requires less frequent dosing. PTU may be chosen in specific situations such as the first trimester of pregnancy or thyroid storm.

Store Neo‑Tomizol tablets at room temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Neo‑Tomizol is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing each day helps maintain stable drug levels. Swallow the tablet whole; do not crush or chew unless directed by a healthcare professional.

The most serious adverse reactions include agranulocytosis, which presents as fever, sore throat or infection, and severe liver injury, indicated by jaundice or abdominal pain. Patients should seek immediate medical attention if they develop these symptoms, as prompt discontinuation of the drug may be required.

Neo‑Tomizol is contraindicated in individuals with known hypersensitivity to carbimazole or methimazole, and in patients with a history of severe liver disease or bone marrow suppression. Caution is also advised for those with pre‑existing blood disorders, and the medication should be avoided unless clearly indicated in pregnancy after risk‑benefit assessment.